Combination therapy in pulmonary arterial hypertension

Clinics in Chest Medicine

Volumn 34, Issue 4, 2013, Pages 841-855

  Pugh, Meredith E ^a   Hemnes, Anna R ^a   Robbins, Ivan M ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Combination therapy; Endothelin receptor antagonists; Phosphodiesterase 5 inhibitors; Prostacyclin; Pulmonary arterial hypertension; Treatment

Indexed keywords

ANOREXIGENIC AGENT; BERAPROST; BOSENTAN; ENDOTHELIN RECEPTOR ANTAGONIST; ILOPROST; IMATINIB; MACITENTAN; NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROSTANOID; RIOCIGUAT; SELEXIPAG; SILDENAFIL; TADALAFIL; TREPROSTINIL;

ADD ON THERAPY; COMPARATIVE EFFECTIVENESS; DIARRHEA; DOSE RESPONSE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EXERCISE; FLUSHING; HUMAN; HYPERTRANSAMINASEMIA; LEG EDEMA; LUNG HEMODYNAMICS; MEDICATION THERAPY MANAGEMENT; MONOTHERAPY; MORTALITY; NAUSEA; OXYGEN SATURATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

COMBINATION THERAPY; ENDOTHELIN RECEPTOR ANTAGONISTS; PHOSPHODIESTERASE-5 INHIBITORS; PROSTACYCLIN; PULMONARY ARTERIAL HYPERTENSION; TREATMENT;

DRUG THERAPY, COMBINATION; EPOPROSTENOL; HUMANS; HYPERTENSION, PULMONARY; PHOSPHODIESTERASE 5 INHIBITORS; PROSTAGLANDINS; RECEPTORS, ENDOTHELIN;

EID: 84888197179     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2013.08.007     Document Type: Review

References (61)

1. Humbert M., Sitbon O., Simonneau G. Treatment of pulmonary arterial hypertension. NEngl J Med 2004, 351:1425-1436.
2. Barst R.J., Gibbs J.S., Ghofrani H.A., et al. Updated evidence-based treatment algorithm in pulmonary arterial hypertension. JAm Coll Cardiol 2009, 54:S78-S84.
3. Barst R.J., Rubin L.J., Long W.A., et al. Acomparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. NEngl J Med 1996, 334:296-301.
4. Rubin L.J., Badesch D.B., Barst R.J., et al. Bosentan therapy for pulmonary arterial hypertension. NEngl J Med 2002, 346:896-903.
5. Simonneau G., Barst R.J., Galie N., et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002, 165:800-804.
6. Galie N., Olschewski H., Oudiz R.J., et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008, 117:3010-3019.
7. Galie N., Ghofrani H.A., Torbicki A., et al. Sildenafil citrate therapy for pulmonary arterial hypertension. NEngl J Med 2005, 353:2148-2157.
8. Olschewski H., Simonneau G., Galie N., et al. Inhaled iloprost for severe pulmonary hypertension. NEngl J Med 2002, 347:322-329.
9. Galie N., Brundage B.H., Ghofrani H.A., et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009, 119:2894-2903.
10. McLaughlin V.V., Archer S.L., Badesch D.B., et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology foundation task force on expert consensus documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc; and the Pulmonary Hypertension Association. JAm Coll Cardiol 2009, 53:1573-1619.
11. Schermuly R.T., Roehl A., Weissmann N., et al. Combination of nonspecific PDE inhibitors with inhaled prostacyclin in experimental pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2001, 281(6):L1361-L1368.
12. Wilkens H., Guth A., Konig J., et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001, 104:1218-1222.
13. Ghofrani H.A., Wiedemann R., Rose F., et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002, 136:515-522.
14. Kuhn K.P., Wickersham N.E., Robbins I.M., et al. Acute effects of sildenafil in patients with primary pulmonary hypertension receiving epoprostenol. Exp Lung Res 2004, 30:135-145.
15. Badesch D.B., Raskob G.E., Elliott C.G., et al. Pulmonary arterial hypertension: baseline characteristics from the reveal registry. Chest 2010, 137:376-387.
16. Hoeper M.M., Taha N., Bekjarova A., et al. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids. Eur Respir J 2003, 22:330-334.
17. Seyfarth H.J., Pankau H., Hammerschmidt S., et al. Bosentan improves exercise tolerance and Tei index in patients with pulmonary hypertension and prostanoid therapy. Chest 2005, 128:709-713.
18. Channick R.N., Olschewski H., Seeger W., et al. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension. JAm Coll Cardiol 2006, 48:1433-1437.
19. Provencher S., Sitbon O., Humbert M., et al. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J 2006, 27:589-595.
20. Kemp K., Savale L., O'Callaghan D.S., et al. Usefulness of first-line combination therapy with epoprostenol and bosentan in pulmonary arterial hypertension: an observational study. JHeart Lung Transplant 2012, 31(2):150-158.
21. Akagi S., Matsubara H., Miyaji K., et al. Additional effects of bosentan in patients with idiopathic pulmonary arterial hypertension already treated with high-dose epoprostenol. Circ J 2008, 72:1142-1146.
22. Benza R.L., Rayburn B.K., Tallaj J.A., et al. Treprostinil-based therapy in the treatment of moderate-to-severe pulmonary arterial hypertension: long-term efficacy and combination with bosentan. Chest 2008, 134:139-145.
23. Ivy D.D., Rosenzweig E.B., Lemarie J.C., et al. Long-term outcomes in children with pulmonary arterial hypertension treated with bosentan in real-world clinical settings. Am J Cardiol 2010, 106:1332-1338.
24. Humbert M., Barst R.J., Robbins I.M., et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004, 24:353-359.
25. McLaughlin V.V., Oudiz R.J., Frost A., et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med 2006, 174:1257-1263.
26. Hoeper M.M., Leuchte H., Halank M., et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J 2006, 28:691-694.
27. McLaughlin V.V., Benza R.L., Rubin L.J., et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. JAm Coll Cardiol 2010, 55:1915-1922.
28. Jimenez Lopez-Guarch C., Escribano Subias P., Tello de Meneses R., et al. Efficacy of oral sildenafil as rescue therapy in patients with severe pulmonary arterial hypertension chronically treated with prostacyclin. Long-term results. Rev Esp Cardiol 2004, 57:946-951. [in Spanish].
29. Ruiz M.J., Escribano P., Delgado J.F., et al. Efficacy of sildenafil as a rescue therapy for patients with severe pulmonary arterial hypertension and given long-term treatment with prostanoids: 2-year experience. JHeart Lung Transplant 2006, 25:1353-1357.
30. Ghofrani H.A., Rose F., Schermuly R.T., et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. JAm Coll Cardiol 2003, 42:158-164.
31. Gomberg-Maitland M., McLaughlin V., Gulati M., et al. Efficacy and safety of sildenafil added to treprostinil in pulmonary hypertension. Am J Cardiol 2005, 96:1334-1336.
32. Kataoka M., Satoh T., Manabe T., et al. Oral sildenafil improves primary pulmonary hypertension refractory to epoprostenol. Circ J 2005, 69:461-465.
33. Simonneau G., Rubin L.J., Galie N., et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008, 149:521-530.
34. Copher R., Cerulli A., Watkins A., et al. Treatment patterns and healthcare system burden of managed care patients with suspected pulmonary arterial hypertension in the United States. JMed Econ 2012, 15:947-955.
35. Angalakuditi M., Edgell E., Beardsworth A., et al. Treatment patterns and resource utilization and costs among patients with pulmonary arterial hypertension in the United States. JMed Econ 2010, 13:393-402.
36. Paul G.A., Gibbs J.S., Boobis A.R., et al. Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension. Br J Clin Pharmacol 2005, 60:107-112.
37. Wrishko R.E., Dingemanse J., Yu A., et al. Pharmacokinetic interaction between tadalafil and bosentan in healthy male subjects. JClin Pharmacol 2008, 48:610-618.
38. Spence R., Mandagere A., Harrison B., et al. No clinically relevant pharmacokinetic and safety interactions of ambrisentan in combination with tadalafil in healthy volunteers. JPharm Sci 2009, 98:4962-4974.
39. Gruenig E., Michelakis E., Vachiery J.L., et al. Acute hemodynamic effects of single-dose sildenafil when added to established bosentan therapy in patients with pulmonary arterial hypertension: results of the COMPASS-1 study. JClin Pharmacol 2009, 49:1343-1352.
40. Mathai S.C., Girgis R.E., Fisher M.R., et al. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. Eur Respir J 2007, 29:469-475.
41. Porhownik N.R., Al-Sharif H., Bshouty Z. Addition of sildenafil in patients with pulmonary arterial hypertension with inadequate response to bosentan monotherapy. Can Respir J 2008, 15:427-430.
42. Keogh A., Strange G., Kotlyar E., et al. Survival after the initiation of combination therapy in patients with pulmonary arterial hypertension: an Australian collaborative report. Intern Med J 2011, 41:235-244.
43. Hoeper M.M., Faulenbach C., Golpon H., et al. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J 2004, 24:1007-1010.
44. Minai O.A., Arroliga A.C. Long-term results after addition of sildenafil in idiopathic PAH patients on bosentan. South Med J 2006, 99:880-883.
45. Launay D., Sitbon O., Le Pavec J., et al. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Rheumatology (Oxford) 2010, 49:490-500.
46. Lunze K., Gilbert N., Mebus S., et al. First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension. Eur J Clin Invest 2006, 36(Suppl 3):32-38.
47. D'Alto M., Romeo E., Argiento P., et al. Bosentan-sildenafil association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisenmenger physiology. Int J Cardiol 2012, 155:378-382.
48. Iversen K., Jensen A.S., Jensen T.V., et al. Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. Eur Heart J 2010, 31:1124-1131.
49. Barst R.J., Oudiz R.J., Beardsworth A., et al. Tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension. JHeart Lung Transplant 2011, 30:632-643.
50. Ghofrani H.A., Morrell N.W., Hoeper M.M., et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 2010, 182(9):1171-1177.
51. Hoeper M.M., Barst R.J., Bourge R.C., et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulation 2013, 127:1128-1138.
52. Simonneau G., Torbicki A., Hoeper M.M., et al. Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J 2012, 40(4):874-880.
53. Tapson V.F., Jing Z.C., Xu K.F., Rubin On Behalf of the FREEDOM-C2 Study Team Oral treprostinil for the treatment of pulmonary arterial hypertension in patients on background endothelin receptor antagonist and/or phosphodiesterase type 5 inhibitor therapy (The FREEDOM-C2 study): a randomized controlled trial. Chest 2013, 144:952-958.
54. Suleman N., Frost A.E. Transition from epoprostenol and treprostinil to the oral endothelin receptor antagonist bosentan in patients with pulmonary hypertension. Chest 2004, 126:808-815.
55. Steiner M.K., Preston I.R., Klinger J.R., et al. Conversion to bosentan from prostacyclin infusion therapy in pulmonary arterial hypertension: a pilot study. Chest 2006, 130:1471-1480.
56. Safdar Z. Outcome of pulmonary hypertension subjects transitioned from intravenous prostacyclin to oral bosentan. Respir Med 2009, 103:1688-1692.
57. Ivy D.D., Doran A., Claussen L., et al. Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan. Am J Cardiol 2004, 93:943-946.
58. Johnson R.F., Loyd J.E., Mullican A.L., et al. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension. JHeart Lung Transplant 2007, 26:363-369.
59. Keogh A.M., Jabbour A., Weintraub R., et al. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension. JHeart Lung Transplant 2007, 26:1079-1083.
60. Diaz-Guzman E., Heresi G.A., Dweik R.A., et al. Long-term experience after transition from parenteral prostanoids to oral agents in patients with pulmonary hypertension. Respir Med 2008, 102:681-689.
61. Bai Y., Sun L., Hu S., et al. Combination therapy in pulmonary arterial hypertension: a meta-analysis. Cardiology 2011, 120:157-165.